North America Ophthalmic Drugs Market Size & Outlook
North America ophthalmic drugs market, 2018-2030 (US$M)
Related Markets
North America ophthalmic drugs market highlights
- The North America ophthalmic drugs market generated a revenue of USD 17,014.9 million in 2023.
- The market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2023.
- Gene & Cell Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 17,014.9 million |
| Market revenue in 2030 | USD 28,287.6 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Gene & Cell Therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-inflammatory, Anti-glaucoma, Gene & Cell Therapy |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 45.0% of the global ophthalmic drugs market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 16,136.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America ophthalmic drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 32.52% in 2023. Horizon Databook has segmented the North America ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-inflammatory, anti-glaucoma, gene & cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
North America held the largest share of 44.30% of ophthalmic drugs market in 2022 owing to factors such as the rising prevalence of eye diseases and favorable government initiatives in the region. North America is a developed region with high healthcare expenditure.
High healthcare costs are among the primary factors driving market growth and boosting the demand for fast-acting and high-efficacy drugs. A growing emphasis on personalized medicine, increasing collaborations & externalizations with academic research institutes, and rapid adoption of healthcare IT are some of the other factors anticipated to further propel the market growth in the region.
Reasons to subscribe to North America ophthalmic drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America ophthalmic drugs market databook
-
Our clientele includes a mix of ophthalmic drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America ophthalmic drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America ophthalmic drugs market size, by country, 2018-2030 (US$M)
North America Ophthalmic Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
